Biotech

All Articles

TPG tops up funds to $580M for expenditures all over lifestyle scientific researches

.Possession supervisor TPG, which has assisted biotechs such as Sionna Rehabs and Santa Clam Ana Bio...

Merck quits stage 3 TIGIT trial in bronchi cancer for impossibility

.Merck &amp Co.'s TIGIT plan has endured one more drawback. Months after shuttering a stage 3 most c...

After a challenging year, Exscientia folds up in to Recursion

.After a year determined through pipe cuts, the shift of its own CEO as well as layoffs, Exscientia ...

Cullinan, after $25M deal, hands back bispecific to Harbour

.Cullinan Therapy was actually wowed enough with Port BioMed's bispecific immune system reactor that...

A deeper take a look at Intense Biotech's Intense 15

.In this particular full week's episode of "The Best Line," we're diving into Brutal Biotech's yearl...

Lilly encounters stage 2 failure of tau-targeting med

.The confetti is still soaring from Eli Lilly's celebration commemorating the commendation of Alzhei...

Biogen CMO Maha Radhakrishnan joins Sofinnova-- Chutes &amp Ladders

.Invite to recently's Chutes &amp Ladders, our summary of significant management hirings, firings as...

Lykos are going to talk to FDA to reexamine its own choice adhering to turndown of MDMA therapy for post-traumatic stress disorder

.Observing an unsatisfactory showing for Lykos Therapies' MDMA candidate for trauma at a current FDA...

AN 2 halves headcount, stops period 3 test after records disappoint

.AN2 Therapies is reconsidering its own organization in feedback to dull midphase data, pledging to ...

Merck pays out $700M for bispecific, spying autoimmune opening as well as possibility to challenge Amgen in cancer cells

.Merck &amp Co. is spending $700 thousand beforehand to test Amgen in a blood cancer cells market. T...